Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment

Janssen Pharmaceuticals of Johnson & Johnson (J&J), a dominant player in the biopharmaceutical space, announced on 17 March 2023 its latest findings from real-world data analyses of Tremfya (guselkumab), a monoclonal antibody that binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor in bio-naïve and bio-experienced patients with moderate-to-severe plaque psoriasis (PsO) who are eligible to receive systemic therapy or phototherapy. According to the reported data, Tremfya exhibited superior long-term management of PsO symptoms compared to IL-17 inhibitors secukinumab and ixekizumab, as well as resulted in greater improvements in quality of life (Johnson & Johnson, 2023).